Daniel R. Day advises Avalere clients on changes to FDA frameworks, scientific due diligence reviews, and regulatory strategy.
Daniel also has special expertise in bringing analysis and insight into impending federal health legislation.
Prior to joining Avalere, he served as a member of the Scientific Advisory Board and program coordinator with Terosin Group, Inc., and as a visiting scientist at the University of California at Santa Barbara.
Daniel has a PhD in pharmacology, an MA in molecular cellular biology, and a BS in biological sciences from the University of California at Santa Barbara.
Authored Content
This past spring, Avalere and MITRE experts presented “Implementation of the Core Quality Measures Collaborative (CQMC) Core Measure Sets by Public Payers: Successes and Opportunities” at the Pharmacy Quality Alliance (PQA) annual meeting.
Cancer is a burden to patients and the healthcare system. Last year, an estimated 1.6 million new cancer cases were diagnosed in the U.S and the latest figures estimate that 13.4 million people, about 4 percent of the U.S. population, live with cancer in the U.S.1
To help you organize the chaos of the ever-evolving quality measures landscape, we are pleased to introduce the Avalere Quality Measures Navigator (QMN).